Focus: Axiom is a San Francisco-based public biotechnology company specializing in AI-driven toxicity modeling with a diversified pipeline across neurology, ophthalmology, infectious diseases, and gastroenterology. The company operates at a small scale with limited disclosed headcount and minimal cash reserves.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Axiom presents a high-risk, high-upside opportunity suited only for early-career scientists willing to bet on AI-enabled drug discovery at a cash-constrained public biotech.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Axiom
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Axiom's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles